This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aytac, U. Articles by Dang, N. H. Search for Related Content PubMed PubMed Citation Articles by Aytac, U. Articles by Dang, N. H.

Expression of CD26 and Its Associated Dipeptidyl Peptidase IV Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Cell Cycle Arrest at the G₂/M Checkpoint¹

Departments of Lymphoma/Myeloma [U. A., K. S., F. C., N. H. D.], Gastrointestinal Oncology [L. H.], and Molecular Therapeutics [F-X. C., G. B. M., N. H. D.], M. D. Anderson Cancer Center, Houston, Texas 77030; and Department of Clinical Immunology and AIDS Research Center, Institute of Medical Science-University of Tokyo 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan [K. O., C. M.]

CD26, a M_r 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array of diverse functional properties, with a role in T-cell physiology and the development of certain human cancers. In this study, we report that surface expression of CD26, through its associated DPPIV enzyme activity, enhanced sensitivity of Jurkat T-cell transfectants to G₂-M arrest induced by the chemotherapeutic drug, doxorubicin. This was associated with disruption of cell cycle-related events, including hyperphosphorylation and inhibition of p34^cdc2 kinase activity, phosphorylation of cdc25C, and alteration in cyclin B1 expression. In addition, we demonstrate that the addition of exogenous soluble DPPIV enhanced sensitivity of lymphoid tumor cell lines to doxorubicin, suggesting a potentially useful clinical role for CD26/DPPIV in the treatment of selected human hematological malignancies.

This article has been cited by other articles:

				D. J. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action Diabetes Care, June 1, 2007; 30(6): 1335 - 1343. [Full Text] [PDF]

				T. Sato, T. Yamochi, T. Yamochi, U. Aytac, K. Ohnuma, K. S. McKee, C. Morimoto, and N. H. Dang CD26 Regulates p38 Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Integrin {beta}1, Adhesion to Extracellular Matrix, and Tumorigenicity of T-Anaplastic Large Cell Lymphoma Karpas 299 Cancer Res., August 1, 2005; 65(15): 6950 - 6956. [Abstract] [Full Text] [PDF]

				T. Yamochi, T. Yamochi, U. Aytac, T. Sato, K. Sato, K. Ohnuma, K. S. McKee, C. Morimoto, and N. H. Dang Regulation of p38 Phosphorylation and Topoisomerase II{alpha} Expression in the B-Cell Lymphoma Line Jiyoye by CD26/Dipeptidyl Peptidase IV Is Associated with Enhanced In vitro and In vivo Sensitivity to Doxorubicin Cancer Res., March 1, 2005; 65(5): 1973 - 1983. [Abstract] [Full Text] [PDF]

				T. Yamochi, T. Yamochi, U. Aytac, T. Sato, C. Morimoto, and N. H. Dang CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 3407 - 3407. [Abstract]

				D. Aldinucci, D. Poletto, D. Lorenzon, P. Nanni, M. Degan, K. Olivo, B. Rapana, A. Pinto, and V. Gattei CD26 Expression Correlates with a Reduced Sensitivity to 2'-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas Clin. Cancer Res., January 15, 2004; 10(2): 508 - 520. [Abstract] [Full Text] [PDF]

				H. Kajiyama, F. Kikkawa, E. Khin, K. Shibata, K. Ino, and S. Mizutani Dipeptidyl Peptidase IV Overexpression Induces Up-Regulation of E-Cadherin and Tissue Inhibitors of Matrix Metalloproteinases, Resulting in Decreased Invasive Potential in Ovarian Carcinoma Cells Cancer Res., May 1, 2003; 63(9): 2278 - 2283. [Abstract] [Full Text] [PDF]